Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-approval long-term safety and efficacy study of repeat darvadstrocel in Crohn's disease with complex perianal fistulas
MOH_2021-05-13_009887Phase 4Not yet recruiting
- Sponsor
- Millennium Pharmaceuticals, Inc (MPI)
- Start
- May 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of darvadstrocel in Crohn's disease and anal fistula, sponsored by Millennium Pharmaceuticals, Inc (MPI). Primary endpoint: Long-term safety of repeat darvadstrocel administration. Planned start May 2021; status: not yet recruiting.
02
Drugs
darvadstrocel
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on MOH_2021-05-13_009887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-13_009887.